Cite
HARVARD Citation
Fujiwara, K. et al. (n.d.). 264TiPENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer. Annals of oncology. p. . [Online].